GlassScriptPhysician profile
Patrick Stephen Mcgrade
NPI 1982164802
$19,344.56
in general payments reported to CMS, 2019-2025
24 companies · $4,154 in 2025
The $4,154 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $205 · 2022: $552 · 2023: $357 · 2024: $14K · 2025: $4,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $14K · Food and Beverage: $3,942 · Grant: $800 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $13,611.67 |
| Food and Beverage | $3,942.02 |
| Grant | $800.00 |
| Education | $234.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $12,929.00 | 2024-2025 | (9520) Igt Devices Undivided, (6554) Peripheral Vascular Undivided, (Bh4) Igt Devices Undivided |
| Boston Scientific Corporation | $2,485.49 | 2025 | Watchman Access System, General - Catheter, Avvigo Guidance System |
| Medtronic, INC. | $905.89 | 2024-2025 | Corevalve Evolut R, Symplicity G3, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $746.37 | 2023-2025 | Ensite, Cardiomems, Ultreon |
| Abiomed | $730.34 | 2022-2025 | Impella |
| Novo Nordisk INC | $329.42 | 2020-2024 | Wegovy |
| Novartis Pharmaceuticals Corporation | $310.72 | 2022-2025 | |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| Alnylam Pharmaceuticals INC. | $135.06 | 2025 | Onpattro |
| Aurinia Pharma U.S., INC. | $123.19 | 2022 | |
| Pfizer INC. | $88.94 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.50 | 2022-2025 | Lifevest |
| Teleflex LLC | $43.04 | 2022-2024 | Bandit, Trapliner |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.14 | 2022-2024 | Jardiance |
| Amgen INC. | $37.31 | 2023-2025 | Repatha |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $34.77 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.00 | 2022 | |
| Acist Medical Systems, INC. | $29.16 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.02 | 2023 | Xarelto |
| W. L. Gore & Associates, INC. | $21.56 | 2025 | Gore Cardioform Septal Occluder |
| Astellas Pharma US INC | $21.31 | 2022 | |
| Cardiva Medical, INC. | $20.49 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Edwards Lifesciences Corporation | $20.00 | 2025 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mcgrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.